128
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies

      research-article
      1 , 2 , 3 , 1 , 4 , 5 , 6 , 7 , 6 , 8 , 2 , 3 , 2 , 3 , 7 , 9 , 10 , 5 , 11 , 6 , 5 , 10 , 7 , 12 , 4 , 9 , 13 , 9 , 14 , 15 , 16 , 17 , 15 , 15 , 18 , 5 , 15 , 7 , 8 , 11 , 6 , 19 , 20 , 21 , 16 , 9 , 22 , 23 , 14 , 1 , 22 , 11 , 2 , 3 , 5 , 1 , 22 ,
      BMC Endocrine Disorders
      BioMed Central
      Harmonization, Obesity, Metabolic syndrome, Cardiovascular disease, Metabolically healthy

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2 diabetes or cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the consequences of (healthy) obesity using data on risk factors and phenotypes across several large-scale cohort studies. Aim of this study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically healthy obesity (MHO) in ten participating studies.

          Methods

          Ten different cohorts in seven countries were combined, using data transformed into a harmonized format. All participants were of European origin, with age 18–80 years. They had participated in a clinical examination for anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of lipids and glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m 2) based on the 2001 NCEP ATP III criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the MetS components, and no previous diagnosis of cardiovascular disease.

          Results

          Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence of obesity varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized percentage of obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort, and in men from 43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently occurring factor contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO varied in women from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was more prevalent in women than in men, and decreased with age in both sexes.

          Conclusions

          Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key characteristics defining the metabolically healthy obese phenotype across ten cohort studies. There is considerable variability in the prevalence of healthy obesity across the different European populations studied, even when unified criteria were used to classify this phenotype.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

          Obesity and diabetes are increasing in the United States. To estimate the prevalence of obesity and diabetes among US adults in 2001. Random-digit telephone survey of 195 005 adults aged 18 years or older residing in all states participating in the Behavioral Risk Factor Surveillance System in 2001. Body mass index, based on self-reported weight and height and self-reported diabetes. In 2001 the prevalence of obesity (BMI > or =30) was 20.9% vs 19.8% in 2000, an increase of 5.6%. The prevalence of diabetes increased to 7.9% vs 7.3% in 2000, an increase of 8.2%. The prevalence of BMI of 40 or higher in 2001 was 2.3%. Overweight and obesity were significantly associated with diabetes, high blood pressure, high cholesterol, asthma, arthritis, and poor health status. Compared with adults with normal weight, adults with a BMI of 40 or higher had an odds ratio (OR) of 7.37 (95% confidence interval [CI], 6.39-8.50) for diagnosed diabetes, 6.38 (95% CI, 5.67-7.17) for high blood pressure, 1.88 (95% CI,1.67-2.13) for high cholesterol levels, 2.72 (95% CI, 2.38-3.12) for asthma, 4.41 (95% CI, 3.91-4.97) for arthritis, and 4.19 (95% CI, 3.68-4.76) for fair or poor health. Increases in obesity and diabetes among US adults continue in both sexes, all ages, all races, all educational levels, and all smoking levels. Obesity is strongly associated with several major health risk factors.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The metabolic syndrome.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Identification and characterization of metabolically benign obesity in humans.

              Obesity represents a risk factor for insulin resistance, type 2 diabetes mellitus, and atherosclerosis. In addition, for any given amount of total body fat, an excess of visceral fat or fat accumulation in the liver and skeletal muscle augments the risk. Conversely, even in obesity, a metabolically benign fat distribution phenotype may exist. In 314 subjects, we measured total body, visceral, and subcutaneous fat with magnetic resonance (MR) tomography and fat in the liver and skeletal muscle with proton MR spectroscopy. Insulin sensitivity was estimated from oral glucose tolerance test results. Subjects were divided into 4 groups: normal weight (body mass index [BMI] [calculated as weight in kilograms divided by height in meters squared], or = 30.0 and placement in the upper quartile of insulin sensitivity), and obese-insulin resistant (IR) (BMI, > or = 30.0 and placement in the lower 3 quartiles of insulin sensitivity). Total body and visceral fat were higher in the overweight and obese groups compared with the normal-weight group (P < .05); however, no differences were observed between the obese groups. In contrast, ectopic fat in skeletal muscle (P < .001) and particularly the liver (4.3% +/- 0.6% vs 9.5% +/- 0.8%) and the intima-media thickness of the common carotid artery (0.54 +/- 0.02 vs 0.59 +/- 0.01 mm) were lower and insulin sensitivity was higher (17.4 +/- 0.9 vs 7.3 +/- 0.3 arbitrary units) in the obese-IS vs the obese-IR group (P < .05). Unexpectedly, the obese-IS group had almost identical insulin sensitivity and the intima-media thickness was not statistically different compared with the normal-weight group (18.2 +/- 0.9 AU and 0.51 +/- 0.02 mm, respectively). A metabolically benign obesity that is not accompanied by insulin resistance and early atherosclerosis exists in humans. Furthermore, ectopic fat in the liver may be more important than visceral fat in the determination of such a beneficial phenotype in obesity.
                Bookmark

                Author and article information

                Journal
                BMC Endocr Disord
                BMC Endocr Disord
                BMC Endocrine Disorders
                BioMed Central
                1472-6823
                2014
                1 February 2014
                : 14
                : 9
                Affiliations
                [1 ]Department of Endocrinology, University of Groningen, University Medical Center Groningen, HPC AA31, P.O. Box 30001, Groningen RB 9700, The Netherlands
                [2 ]Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
                [3 ]Unit of Public Health Genomics, National Institute for Health and Welfare, Helsinki, Finland
                [4 ]Research Institute of the McGill University of Health Centre, Montreal, Canada
                [5 ]University of Tartu, Estonian Genome Center, Tartu, Estonia
                [6 ]Center for Biomedicine, European Academy of Bolzano/Bozen (EURAC), Bolzano, Italy
                [7 ]Data to Knowledge Research Group, School of Social and Community Medicine, University of Bristol, Bristol, UK
                [8 ]Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
                [9 ]Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                [10 ]Genomics Coordination Center, University of Groningen, Groningen Bioinformatics Center, and University Medical Center Groningen, Groningen, The Netherlands
                [11 ]Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
                [12 ]Ontario Institute for Cancer Research, Toronto, ON, Canada
                [13 ]Department of Genes and Environment, Division of Epidemiology, The Norwegian Institute of Public Health, Oslo, Norway
                [14 ]Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                [15 ]HUNT Research Center, Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
                [16 ]THL-National Institute for Health and Welfare, Helsinki, Finland
                [17 ]Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                [18 ]Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
                [19 ]Department of Neurology, Central Hospital, Bolzano, Italy
                [20 ]Department of Neurology, University of Lübeck, Lübeck, Germany
                [21 ]Pirkanmaa hospital district and Finnish Diabetes Association, Tampere, Finland
                [22 ]University of Groningen, University Medical Center Groningen, LifeLines Cohort Study, Groningen, The Netherlands
                [23 ]Institute of Public Health and Clinical Nutrition, University of Eastern Finland, and Research Unit, Kuopio University Hospital, Kuopio, Finland
                Article
                1472-6823-14-9
                10.1186/1472-6823-14-9
                3923238
                24484869
                f821f6ac-bd27-42b4-a7f7-22a70c8cbae7
                Copyright © 2014 van Vliet-Ostaptchouk et al.; licensee BioMed Central Ltd.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 26 January 2014
                : 27 January 2014
                Categories
                Research Article

                Endocrinology & Diabetes
                obesity,harmonization,metabolically healthy,cardiovascular disease,metabolic syndrome

                Comments

                Comment on this article